Orthocell Limited
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| OCC.AX | CNXU | CLGN | LCTX | VCEL | MESO | |
|---|---|---|---|---|---|---|
| Market cap | 151.18M | 68.45M | 12.18M | 260.49M | 2.33B | 1.86B |
| P/E (TTM) | — | — | — | — | 96.8 | — |
| Forward P/E | -23.6 | -4.2 | -10.8 | -7.5 | 53.8 | 31.4 |
| Price/book | 4.4 | 10.4 | 2.1 | 4.3 | 6.3 | 3.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −52.21% | −83.01% | −80.60% | −40.46% | +10.46% | −4.29% |
| Today | +2.78% | −6.72% | +2.92% | +1.98% | +10.68% | −3.25% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All OCC.AX news ›Orthocell partner receives US FDA clearance for marine-derived bone graft
Orthocell’s partner Marine Biomedical has secured key US FDA clearance. Pic: Getty Images. Special Report: Orthocell’s strategic partner Marine Biomedical has received US Food and Drug Administration (FDA) 510(k) clearance for PearlBone, a…
Orthocell records strongest US Remplir sales month as adoption gathers pace
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has delivered its strongest month of US Remplir™ sales since launch, with 92 units sold in October generating A$279,000 in revenue as surgeon adoption and hospital access continued to build. October sales…
Orthocell gains US bone repair exposure as PearlBone wins FDA clearance
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has gained further exposure to the US regenerative medicine market after strategic partner Marine Biomedical received US Food and Drug Administration 510(k) clearance for its PearlBone bone graft…
Orthocell Partner Marine Biomedical Achieves U.S. FDA Clearance for PearlBone™
Sharecafe Orthocell Partner Marine Biomedical Achieves U.S. FDA Clearance for PearlBone™ Orthocell Ltd (ASX: OCC), a regenerative medicine company focused on regenerating mobility for patients by developing products for
Orthocell records strongest monthly US Remplir sales since launch
OCC has posted a record month of Remplir sales in the US. Pic: Getty Images. Special Report: Orthocell has recorded its strongest month of US sales for its flagship nerve repair product Remplir since launch, with 92 units sold in October…
Orthocell bets on prostate surgery as five patient pilot paves way for US push
Perth-based regenerative medicine company Orthocell says its nerve repair device could open a new market in prostate cancer surgery. The company told investors that Remplir, its collagen device already approved for peripheral nerve…
Small Cap Watch: Orthocell reports promising prostate surgery recovery data as Pilbara Gold extends high-grade discovery
The S&P/ASX Small Ordinaries Index (ASX) edged lower in its latest session as investors weighed developments across the healthcare and resources sectors, including promising clinical results from Orthocell, further high-grade gold…
Daily Special: Orthocell, WA Gold, PainChek, Piche Resources, CurveBeam AI
Finance News Network by Finance News Network October 13, 2026 12:58 PM
Orthocell nerve repair product Remplir shows promise in prostate cancer surgery
Orthocell’s Remplir is showing promise in protecting nerves in prostatectomy procedures. Pic: Getty Images Special Report: Orthocell has received encouraging early functional recovery outcomes from an initial five-patient case series…
Orthocell's Remplir shows promising results in prostate cancer surgery, targeting a $2B US market expansion.
Orthocell Ltd reported positive early clinical results for its Remplir nerve repair technology in prostate cancer surgery, with 80% of patients regaining urinary continence and 75% showing erectile function recovery. The initial…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- proactiveinvestors.com3
- sharecafe.com.au2
- stockhead.com.au2
- biotechdispatch.com.au1
- finnewsnetwork.com.au1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.